Pharma-Bio Serv Profit Margin

Pharma-Bio Serv (PBSV) currently reports a profit margin of -147.13% as of July 2026. That compares with -0.92% in the prior-year period — down 15939.9% year over year. That is below the sector sector average of 13.2%. Use the charts on this page to explore Pharma-Bio Serv's profit margin history and peer comparisons.

Pharma-Bio Serv's profit margin decreased from -0.92% to -147.13% — a 15939.9% year-over-year decrease (period ending July 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pharma-Bio Serv's profit margin of -147.13% is lower than the its sector sector average of 13.2%. That is roughly 1214.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Pharma-Bio Serv's current -147.13% should be judged against industry norms (sector average: 13.2%) and against PBSV's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -147.13%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.2%. From there, open related valuation or income-statement pages for Pharma-Bio Serv, and consider following PBSV for alerts when major investors trade the stock.